bluuebunny/crossref_metadata_2025 huggingface dataset:
Data from Educational Attainment and Cancer Incidence in a Large Nationwide Prospective Cohort
Authors: Hodge James M. , Patel Alpa V. , Islami Farhad , Jemal Ahmedin , Hiatt Robert A.
Published: December 2023

AbstractBackground:
Educational attainment is a social determinant of health and frequently used as an indicator of socioeconomic status. Educational attainment is a predictor of cancer mortality, but associations with site-specific cancer incidence are variable. The aim of this study was to evaluate the association of educational attainment and site-specific cancer incidence adjusting for known risk factors in a large prospective cohort.
Methods:
Men and women enrolled in the American Cancer Society's Cancer Prevention Study-II Nutrition Cohort who were cancer free at baseline were included in this study (n = 148,965). Between 1992 and 2017, 22,810 men and 17,556 women were diagnosed with incident cancer. Cox proportional hazards regression models were used to estimate age- and multivariable-adjusted risk and 95% confidence intervals of total and site-specific cancer incidence in persons with lower versus higher educational attainment.
Results:
Educational attainment was inversely associated with age-adjusted cancer incidence among men but not women. For specific cancer sites, the multivariable-adjusted risk of cancer in the least versus most educated individuals remained significant for colon, rectum, and lung cancer among men and lung and breast cancer among women.
Conclusions:
Educational attainment is associated with overall and site-specific cancer risk though adjusting for cancer risk factors attenuates the association for most cancer sites.
Impact:
This study provides further evidence that educational attainment is an important social determinant of cancer but that its effects are driven by associated behavioral risk factors suggesting that targeting interventions toward those with lower educational attainment is an important policy consideration.
Trial protocol 1 from Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency
Authors: Das Anirban , Tabori Uri , Sambira Nahum Lauren C. , Collins Natalie B. , Deyell Rebecca , Dvir Rina , Faure-Conter Cecile , Hassall Timothy E. , Minturn Jane E. , Edwards Melissa , Brookes Elissa , Bianchi Vanessa , Levine Adrian , Stone Simone C. , Sudhaman Sumedha , Sanchez Ramirez Santiago , Ercan Ayse B. , Stengs Lucie , Chung Jill , Negm Logine , Getz Gad , Maruvka Yosef E. , Ertl-Wagner Birgit , Ohashi Pamela S. , Pugh Trevor , Hawkins Cynthia , Bouffet Eric , Morgenstern Daniel A.
Published: December 2023

Full trial protocol NCT02992964
Supplemental Figure S1 from Genetic Predictors of Ibrutinib-related Cardiovascular Side Effects in Patients with Chronic Lymphocytic Leukemia
Authors: Hamadeh Issam S. , Patel Jai N. , Jacobs Ryan , Zeng Hang , He Jiaxian , Hu Bei , Moyo Tamara Kay , Soni Amy , Park Steven , Copelan Ed , Avalos Belinda , Hamilton Alicia , Steuerwald Nury , Ghosh Nilanjan
Published: December 2023

Figure S1. Ingenuity Pathway Analysis of Genes within the BTK Pathway Potentially Related to Cardiovascular Side Effects
Supplementary Data 1 from HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer
Authors: Jiang Tao , Jin Qiqi , Wang Jiahao , Wu Fengying , Chen Jian , Chen Gongyan , Huang Yunchao , Chen Jianhua , Cheng Ying , Wang QiMing , Pan Yueyin , Zhou Jianying , Shi Jianhua , Xu Xingxiang , Lin LiZhu , Zhang Wei , Zhang Yiping , Liu Yunpeng , Fang Yong , Feng Jifeng , Wang Zhehai , Hu Sheng , Fang Jian , Shu Yongqian , Cui Jiuwei , Hu Yi , Yao Wenxiu , Li Xingya , Lin Xiaoyan , Wang Rui , Wang Yongsheng , Shi Wei , Feng Gaohua , Ni Jun , Mao Beibei , Ren Dandan , Sun Huaibo , Zhang Henghui , Chen Luonan , Zhou Caicun , Ren Shengxiang
Published: December 2023

Supplementary Materials
Supplementary Table S3 from Tamoxifen Response at Single-Cell Resolution in Estrogen Receptor–Positive Primary Human Breast Tumors
Authors: Kim Hyunsoo , Whitman Austin A. , Wisniewska Kamila , Kakati Rasha T. , Garcia-Recio Susana , Calhoun Benjamin C. , Franco Hector L. , Perou Charles M. , Spanheimer Philip M.
Published: December 2023

Comparison of tamoxifen and control treated epithelial subpopulations from normal samples
Supplementary Figure S6 from Tamoxifen Response at Single-Cell Resolution in Estrogen Receptor–Positive Primary Human Breast Tumors
Authors: Kim Hyunsoo , Whitman Austin A. , Wisniewska Kamila , Kakati Rasha T. , Garcia-Recio Susana , Calhoun Benjamin C. , Franco Hector L. , Perou Charles M. , Spanheimer Philip M.
Published: December 2023

Prognostic signatures of resistant cell populations.
Supplementary Figure S5 from Tamoxifen Response at Single-Cell Resolution in Estrogen Receptor–Positive Primary Human Breast Tumors
Authors: Kim Hyunsoo , Whitman Austin A. , Wisniewska Kamila , Kakati Rasha T. , Garcia-Recio Susana , Calhoun Benjamin C. , Franco Hector L. , Perou Charles M. , Spanheimer Philip M.
Published: December 2023

Characteristic gene expression profile of tamoxifen resistant clusters.
Supplementary Figure S4 from Tamoxifen Response at Single-Cell Resolution in Estrogen Receptor–Positive Primary Human Breast Tumors
Authors: Kim Hyunsoo , Whitman Austin A. , Wisniewska Kamila , Kakati Rasha T. , Garcia-Recio Susana , Calhoun Benjamin C. , Franco Hector L. , Perou Charles M. , Spanheimer Philip M.
Published: December 2023

Cell type-specific response to tamoxifen in primary human breast tumors.
Supplementary Data 1 from Fibroblast Activation Protein-Targeted Radioligand Therapy with 177Lu-EB-FAPI for Metastatic Radioiodine-Refractory Thyroid Cancer: First-in-Human, Dose-Escalation Study
Authors: Fu Hao , Huang Jingxiong , Zhao Tianzhi , Wang Hongjian , Chen Yuhang , Xu Weizhi , Pang Yizhen , Guo Wei , Sun Long , Wu Hua , Xu Pengfei , Su Bishan , Zhang Jingjing , Chen Xiaoyuan , Chen Haojun
Published: December 2023

Figure S1-S6, Table S1-S3
Supplementary Table S8 from Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
Authors: Joaquin Garcia Andrea , Rediti Mattia , Venet David , Majjaj Samira , Kammler Roswitha , Munzone Elisabetta , Gianni Lorenzo , Thürlimann Beat , Laáng István , Colleoni Marco , Loi Sherene , Viale Giuseppe , Regan Meredith M. , Buisseret Laurence , Rothé Françoise , Sotiriou Christos
Published: December 2023

Clinic-pathologic characteristics across the Burstein molecular subtypes.
Supplementary Table S7 from Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
Authors: Joaquin Garcia Andrea , Rediti Mattia , Venet David , Majjaj Samira , Kammler Roswitha , Munzone Elisabetta , Gianni Lorenzo , Thürlimann Beat , Laáng István , Colleoni Marco , Loi Sherene , Viale Giuseppe , Regan Meredith M. , Buisseret Laurence , Rothé Françoise , Sotiriou Christos
Published: December 2023

Clinic-pathologic characteristics across the Bareche molecular subtypes.
Supplementary Table S6 from Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
Authors: Joaquin Garcia Andrea , Rediti Mattia , Venet David , Majjaj Samira , Kammler Roswitha , Munzone Elisabetta , Gianni Lorenzo , Thürlimann Beat , Laáng István , Colleoni Marco , Loi Sherene , Viale Giuseppe , Regan Meredith M. , Buisseret Laurence , Rothé Françoise , Sotiriou Christos
Published: December 2023

Association between different TNBC molecular subtypes.
Supplementary Table S5 from Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
Authors: Joaquin Garcia Andrea , Rediti Mattia , Venet David , Majjaj Samira , Kammler Roswitha , Munzone Elisabetta , Gianni Lorenzo , Thürlimann Beat , Laáng István , Colleoni Marco , Loi Sherene , Viale Giuseppe , Regan Meredith M. , Buisseret Laurence , Rothé Françoise , Sotiriou Christos
Published: December 2023

Cox proportional-hazards models for the comparisons of OS, DFS and BCFI according to CM maintenance and no-CM.
Supplementary Figure 4 from Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-up
Authors: Lindskrog Sia V. , Birkenkamp-Demtröder Karin , Nordentoft Iver , Laliotis George , Lamy Philippe , Christensen Emil , Renner Derrick , Andreasen Tine G. , Lange Naja , Sharma Shruti , ElNaggar Adam C. , Liu Minetta C. , Sethi Himanshu , Aleshin Alexey , Agerbæk Mads , Jensen Jørgen B. , Dyrskjøt Lars
Published: December 2023

Biological characteristics of ctDNA shedding tumors
Supplementary Table S3 from Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
Authors: Joaquin Garcia Andrea , Rediti Mattia , Venet David , Majjaj Samira , Kammler Roswitha , Munzone Elisabetta , Gianni Lorenzo , Thürlimann Beat , Laáng István , Colleoni Marco , Loi Sherene , Viale Giuseppe , Regan Meredith M. , Buisseret Laurence , Rothé Françoise , Sotiriou Christos
Published: December 2023

Clinic-pathologic characteristics of the different TNBC cohorts.
Supplementary Figure 2 from Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-up
Authors: Lindskrog Sia V. , Birkenkamp-Demtröder Karin , Nordentoft Iver , Laliotis George , Lamy Philippe , Christensen Emil , Renner Derrick , Andreasen Tine G. , Lange Naja , Sharma Shruti , ElNaggar Adam C. , Liu Minetta C. , Sethi Himanshu , Aleshin Alexey , Agerbæk Mads , Jensen Jørgen B. , Dyrskjøt Lars
Published: December 2023

Longitudinal ctDNA data for NAC-naïve patient cohort
Supplementary Table S2 from Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
Authors: Joaquin Garcia Andrea , Rediti Mattia , Venet David , Majjaj Samira , Kammler Roswitha , Munzone Elisabetta , Gianni Lorenzo , Thürlimann Beat , Laáng István , Colleoni Marco , Loi Sherene , Viale Giuseppe , Regan Meredith M. , Buisseret Laurence , Rothé Françoise , Sotiriou Christos
Published: December 2023

Bareche’s subtype coefficients across the TNBC cell lines.
Supplementary Table S1 from Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
Authors: Joaquin Garcia Andrea , Rediti Mattia , Venet David , Majjaj Samira , Kammler Roswitha , Munzone Elisabetta , Gianni Lorenzo , Thürlimann Beat , Laáng István , Colleoni Marco , Loi Sherene , Viale Giuseppe , Regan Meredith M. , Buisseret Laurence , Rothé Françoise , Sotiriou Christos
Published: December 2023

The table presents the correlation coefficients between RNA-seq signatures and the total number of reads.
Supplementary Figure S6 from Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
Authors: Joaquin Garcia Andrea , Rediti Mattia , Venet David , Majjaj Samira , Kammler Roswitha , Munzone Elisabetta , Gianni Lorenzo , Thürlimann Beat , Laáng István , Colleoni Marco , Loi Sherene , Viale Giuseppe , Regan Meredith M. , Buisseret Laurence , Rothé Françoise , Sotiriou Christos
Published: December 2023

Cox proportional-hazard analysis for the low-dose CM treatment effect on OS, DRFI and BCFI measures according to the Bareche molecular subtypes.
Supplementary Figure S16 from Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
Authors: Joaquin Garcia Andrea , Rediti Mattia , Venet David , Majjaj Samira , Kammler Roswitha , Munzone Elisabetta , Gianni Lorenzo , Thürlimann Beat , Laáng István , Colleoni Marco , Loi Sherene , Viale Giuseppe , Regan Meredith M. , Buisseret Laurence , Rothé Françoise , Sotiriou Christos
Published: December 2023

Associations between area under the curve (AUC) values for methotrexate (MTX) and the different Bareche TNBC subtypes signature levels.
Supplementary Figure S15 from Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
Authors: Joaquin Garcia Andrea , Rediti Mattia , Venet David , Majjaj Samira , Kammler Roswitha , Munzone Elisabetta , Gianni Lorenzo , Thürlimann Beat , Laáng István , Colleoni Marco , Loi Sherene , Viale Giuseppe , Regan Meredith M. , Buisseret Laurence , Rothé Françoise , Sotiriou Christos
Published: December 2023

Associations between Embryonic Stem Cells (ESC) targets and the different TNBC classifications evaluated with an effect size obtained from logistic regression model.
Supplementary Figure S13 from Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
Authors: Joaquin Garcia Andrea , Rediti Mattia , Venet David , Majjaj Samira , Kammler Roswitha , Munzone Elisabetta , Gianni Lorenzo , Thürlimann Beat , Laáng István , Colleoni Marco , Loi Sherene , Viale Giuseppe , Regan Meredith M. , Buisseret Laurence , Rothé Françoise , Sotiriou Christos
Published: December 2023

Associations between immune cell signatures and the different TNBC classifications evaluated with an effect size obtained from logistic regression model.
Supplementary Figure S11 from Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
Authors: Joaquin Garcia Andrea , Rediti Mattia , Venet David , Majjaj Samira , Kammler Roswitha , Munzone Elisabetta , Gianni Lorenzo , Thürlimann Beat , Laáng István , Colleoni Marco , Loi Sherene , Viale Giuseppe , Regan Meredith M. , Buisseret Laurence , Rothé Françoise , Sotiriou Christos
Published: December 2023

Kaplan-Meier estimates for OS, DFS, DRFI and BCFI measures according to LPBC tumors.
Supplementary Figure S10 from Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
Authors: Joaquin Garcia Andrea , Rediti Mattia , Venet David , Majjaj Samira , Kammler Roswitha , Munzone Elisabetta , Gianni Lorenzo , Thürlimann Beat , Laáng István , Colleoni Marco , Loi Sherene , Viale Giuseppe , Regan Meredith M. , Buisseret Laurence , Rothé Françoise , Sotiriou Christos
Published: December 2023

Associations between immune gene signatures and TILs levels.
Supplementary Table S2 from Upregulation of Indoleamine 2,3-Dioxygenase 1 in Tumor Cells and Tertiary Lymphoid Structures is a Hallmark of Inflamed Non–Small Cell Lung Cancer
Authors: Bessede Alban , Peyraud Florent , Le Moulec Sylvestre , Cousin Sophie , Cabart Mathilde , Chomy François , Rey Christophe , Lara Oren , Odin Ophélie , Nafia Imane , Guegan Jean-Philippe , Italiano Antoine
Published: December 2023

Clinical characteristics of patients from mIF cohort
Supplementary Figure S6 from Upregulation of Indoleamine 2,3-Dioxygenase 1 in Tumor Cells and Tertiary Lymphoid Structures is a Hallmark of Inflamed Non–Small Cell Lung Cancer
Authors: Bessede Alban , Peyraud Florent , Le Moulec Sylvestre , Cousin Sophie , Cabart Mathilde , Chomy François , Rey Christophe , Lara Oren , Odin Ophélie , Nafia Imane , Guegan Jean-Philippe , Italiano Antoine
Published: December 2023

IDO1 is expressed in tertiary lymphoid structures (TLS).
Table 2 from Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)
Authors: Ring Alistair , Kilburn Lucy S. , Pearson Alex , Moretti Laura , Afshari-Mehr Angelica , Wardley Andrew M. , Gurel Bora , Macpherson Iain R. , Riisnaes Ruth , Baird Richard D. , Martin Sue , Roylance Rebecca , Johnson Hannah , Ferreira Ana , Winter Matthew C. , Dunne Kathryn , Copson Ellen , Hickish Tamas , Burcombe Russell , Randle Kat , Serra Violeta , Llop-Guevara Alba , Bliss Judith M. , Turner Nicolas C.
Published: December 2023

Activity according to biomarker subgroups: PFS (median, IQR, months).
Supplementary Table S4 from Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)
Authors: Ring Alistair , Kilburn Lucy S. , Pearson Alex , Moretti Laura , Afshari-Mehr Angelica , Wardley Andrew M. , Gurel Bora , Macpherson Iain R. , Riisnaes Ruth , Baird Richard D. , Martin Sue , Roylance Rebecca , Johnson Hannah , Ferreira Ana , Winter Matthew C. , Dunne Kathryn , Copson Ellen , Hickish Tamas , Burcombe Russell , Randle Kat , Serra Violeta , Llop-Guevara Alba , Bliss Judith M. , Turner Nicolas C.
Published: December 2023

Table S4: Activity according to biomarker subgroups: Progression free survival (median, IQR, months) in patients with BRCA1/2 mutations (germline or somatic)
Supplementary Table ST3 from PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
Authors: Stokes Michael E. , Calvo Veronica , Fujisawa Sho , Dudgeon Crissy , Huang Sharon , Ballal Nupur , Shen Leyi , Gasparek Jennifer , Betzenhauser Matthew , Taylor Simon J. , Staschke Kirk A. , Rigby Alan C. , Mulvihill Mark J. , Bose Nandita , Lightcap Eric S. , Surguladze David
Published: December 2023

RCC PDX model characterization and response to treatment.
Supplementary Fig.S2 from PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
Authors: Stokes Michael E. , Calvo Veronica , Fujisawa Sho , Dudgeon Crissy , Huang Sharon , Ballal Nupur , Shen Leyi , Gasparek Jennifer , Betzenhauser Matthew , Taylor Simon J. , Staschke Kirk A. , Rigby Alan C. , Mulvihill Mark J. , Bose Nandita , Lightcap Eric S. , Surguladze David
Published: December 2023

In vivo characterization of HC-5404.
Supplementary Fig. S5 from PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
Authors: Stokes Michael E. , Calvo Veronica , Fujisawa Sho , Dudgeon Crissy , Huang Sharon , Ballal Nupur , Shen Leyi , Gasparek Jennifer , Betzenhauser Matthew , Taylor Simon J. , Staschke Kirk A. , Rigby Alan C. , Mulvihill Mark J. , Bose Nandita , Lightcap Eric S. , Surguladze David
Published: December 2023

Pericyte markers are suppressed by VEGFR-TKI and HC-5404 combination treatments.
Supplementary Fig. S3 from PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
Authors: Stokes Michael E. , Calvo Veronica , Fujisawa Sho , Dudgeon Crissy , Huang Sharon , Ballal Nupur , Shen Leyi , Gasparek Jennifer , Betzenhauser Matthew , Taylor Simon J. , Staschke Kirk A. , Rigby Alan C. , Mulvihill Mark J. , Bose Nandita , Lightcap Eric S. , Surguladze David
Published: December 2023

In vivo characterization of VEGFR-TKIs.
Supplementary Fig. S1 from PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
Authors: Stokes Michael E. , Calvo Veronica , Fujisawa Sho , Dudgeon Crissy , Huang Sharon , Ballal Nupur , Shen Leyi , Gasparek Jennifer , Betzenhauser Matthew , Taylor Simon J. , Staschke Kirk A. , Rigby Alan C. , Mulvihill Mark J. , Bose Nandita , Lightcap Eric S. , Surguladze David
Published: December 2023

Biochemical kinome selectivity profile of HC-5404.
Supplementary Figure 7 from Suppression of Tumor Cell Lactate-generating Signaling Pathways Eradicates Murine PTEN/p53-deficient Aggressive-variant Prostate Cancer via Macrophage Phagocytosis
Authors: Chaudagar Kiranj , Hieromnimon Hanna M. , Kelley Anne , Labadie Brian , Shafran Jordan , Rameshbabu Srikrishnan , Drovetsky Catherine , Bynoe Kaela , Solanki Ani , Markiewicz Erica , Fan Xiaobing , Loda Massimo , Patnaik Akash
Published: December 2023

PI3Ki/MEKi combination therapy for 72 hours activates Wnt/β-catenin pathway in PTEN/p53-deficient prostate GEMM tumor derived cell lines
Supp Fig 9 from ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC
Authors: Vokes Natalie I. , Galan Cobo Ana , Fernandez-Chas Margarita , Molkentine David , Treviño Santiago , Druker Vitaly , Qian Yu , Patel Sonia , Schmidt Stephanie , Hong Lingzhi , Lewis Jeff , Rinsurongkawong Waree , Rinsurongkawong Vadeerat , Lee J. Jack , Negrao Marcelo V. , Gibbons Don L. , Vaporciyan Ara , Le Xiuning , Wu Jia , Zhang Jianjun , Rigney Una , Iyer Sonia , Dean Emma , Heymach John V.
Published: December 2023

Supp Figure 9. ATM loss enhances STING signaling activation with chemotherapy in murine cell lines.
Supp Fig 5 from ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC
Authors: Vokes Natalie I. , Galan Cobo Ana , Fernandez-Chas Margarita , Molkentine David , Treviño Santiago , Druker Vitaly , Qian Yu , Patel Sonia , Schmidt Stephanie , Hong Lingzhi , Lewis Jeff , Rinsurongkawong Waree , Rinsurongkawong Vadeerat , Lee J. Jack , Negrao Marcelo V. , Gibbons Don L. , Vaporciyan Ara , Le Xiuning , Wu Jia , Zhang Jianjun , Rigney Una , Iyer Sonia , Dean Emma , Heymach John V.
Published: December 2023

Supp Figure 5. Tumor mutational burden (TMB) in ATM mutant vs wild-type tumors.
Supplementary Table 1 from A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy
Authors: Grierson Patrick M. , Suresh Rama , Tan Benjamin , Pedersen Katrina S. , Amin Manik , Park Haeseong , Trikalinos Nikolaos A. , Liu Jingxia , Boice Nicholas , Brown Amberly , Bansod Sapana , Wang-Gillam Andrea , Lim Kian-Huat
Published: December 2023

Representativeness of Study Participants
Supp Fig 1 from ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC
Authors: Vokes Natalie I. , Galan Cobo Ana , Fernandez-Chas Margarita , Molkentine David , Treviño Santiago , Druker Vitaly , Qian Yu , Patel Sonia , Schmidt Stephanie , Hong Lingzhi , Lewis Jeff , Rinsurongkawong Waree , Rinsurongkawong Vadeerat , Lee J. Jack , Negrao Marcelo V. , Gibbons Don L. , Vaporciyan Ara , Le Xiuning , Wu Jia , Zhang Jianjun , Rigney Una , Iyer Sonia , Dean Emma , Heymach John V.
Published: December 2023

Supp Figure 1. Cohort Selection and distribution of ATM mutation class.
Supplementary Table S3 from Potential of Fecal Microbiota Transplantation to Prevent Acute GVHD: Analysis from a Phase II Trial
Authors: Rashidi Armin , Ebadi Maryam , Rehman Tauseef Ur , Elhusseini Heba , Kazadi David , Halaweish Hossam , Khan Mohammad H. , Hoeschen Andrea , Cao Qing , Luo Xianghua , Kabage Amanda J. , Lopez Sharon , Holtan Shernan G. , Weisdorf Daniel J. , Khoruts Alexander , Staley Christopher
Published: December 2023

Jaccard index showing similarity between sets of the most central nodes in FMT and placebo arms at pre-treatment and day 28 post-treatment timepoints
Supplementary Figure S1 from Potential of Fecal Microbiota Transplantation to Prevent Acute GVHD: Analysis from a Phase II Trial
Authors: Rashidi Armin , Ebadi Maryam , Rehman Tauseef Ur , Elhusseini Heba , Kazadi David , Halaweish Hossam , Khan Mohammad H. , Hoeschen Andrea , Cao Qing , Luo Xianghua , Kabage Amanda J. , Lopez Sharon , Holtan Shernan G. , Weisdorf Daniel J. , Khoruts Alexander , Staley Christopher
Published: December 2023

LASSO trace plot
Supplementary Data T1 from Advanced Age in Humans and Mouse Models of Glioblastoma Show Decreased Survival from Extratumoral Influence
Authors: Johnson Margaret , Bell April , Lauing Kristen L. , Ladomersky Erik , Zhai Lijie , Penco-Campillo Manon , Shah Yajas , Mauer Elizabeth , Xiu Joanne , Nicolaides Theodore , Drumm Michael , McCortney Kathleen , Elemento Olivier , Kim Miri , Bommi Prashant , Low Justin T. , Memon Ruba , Wu Jennifer , Zhao Junfei , Mi Xinlei , Glantz Michael J. , Sengupta Soma , Castro Brandyn , Yamini Bakhtiar , Horbinski Craig , Baker Darren J. , Walunas Theresa L. , Schiltz Gary E. , Lukas Rimas V. , Wainwright Derek A.
Published: December 2023

Supplementary Tables
Table S7 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study
Authors: Kobayashi Kazufumi , Ogasawara Sadahisa , Maruta Susumu , Okubo Tomomi , Itokawa Norio , Haga Yuki , Seko Yuya , Moriguchi Michihisa , Watanabe Shunji , Shiko Yuki , Takatsuka Hirokazu , Kanzaki Hiroaki , Koroki Keisuke , Inoue Masanori , Nakamura Masato , Kiyono Soichiro , Kanogawa Naoya , Kondo Takayuki , Suzuki Eiichiro , Ooka Yoshihiko , Nakamoto Shingo , Inaba Yosuke , Ikeda Masafumi , Okabe Shinichiro , Morimoto Naoki , Itoh Yoshito , Nakamura Kazuyoshi , Ito Kenji , Azemoto Ryosaku , Atsukawa Masanori , Itobayashi Ei , Kato Naoya
Published: December 2023

Correlations between relative dose intensity and clinical outcomes of lenvatinib treatment
Table S1 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study
Authors: Kobayashi Kazufumi , Ogasawara Sadahisa , Maruta Susumu , Okubo Tomomi , Itokawa Norio , Haga Yuki , Seko Yuya , Moriguchi Michihisa , Watanabe Shunji , Shiko Yuki , Takatsuka Hirokazu , Kanzaki Hiroaki , Koroki Keisuke , Inoue Masanori , Nakamura Masato , Kiyono Soichiro , Kanogawa Naoya , Kondo Takayuki , Suzuki Eiichiro , Ooka Yoshihiko , Nakamoto Shingo , Inaba Yosuke , Ikeda Masafumi , Okabe Shinichiro , Morimoto Naoki , Itoh Yoshito , Nakamura Kazuyoshi , Ito Kenji , Azemoto Ryosaku , Atsukawa Masanori , Itobayashi Ei , Kato Naoya
Published: December 2023

Representativeness of study participants. This table shows the epidemiology of hepatocellular carcinoma patients in Japan.
Figure S3 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study
Authors: Kobayashi Kazufumi , Ogasawara Sadahisa , Maruta Susumu , Okubo Tomomi , Itokawa Norio , Haga Yuki , Seko Yuya , Moriguchi Michihisa , Watanabe Shunji , Shiko Yuki , Takatsuka Hirokazu , Kanzaki Hiroaki , Koroki Keisuke , Inoue Masanori , Nakamura Masato , Kiyono Soichiro , Kanogawa Naoya , Kondo Takayuki , Suzuki Eiichiro , Ooka Yoshihiko , Nakamoto Shingo , Inaba Yosuke , Ikeda Masafumi , Okabe Shinichiro , Morimoto Naoki , Itoh Yoshito , Nakamura Kazuyoshi , Ito Kenji , Azemoto Ryosaku , Atsukawa Masanori , Itobayashi Ei , Kato Naoya
Published: December 2023

Correlation of Child–Pugh score at baseline and at end of lenvatinib treatment
Figure S2 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study
Authors: Kobayashi Kazufumi , Ogasawara Sadahisa , Maruta Susumu , Okubo Tomomi , Itokawa Norio , Haga Yuki , Seko Yuya , Moriguchi Michihisa , Watanabe Shunji , Shiko Yuki , Takatsuka Hirokazu , Kanzaki Hiroaki , Koroki Keisuke , Inoue Masanori , Nakamura Masato , Kiyono Soichiro , Kanogawa Naoya , Kondo Takayuki , Suzuki Eiichiro , Ooka Yoshihiko , Nakamoto Shingo , Inaba Yosuke , Ikeda Masafumi , Okabe Shinichiro , Morimoto Naoki , Itoh Yoshito , Nakamura Kazuyoshi , Ito Kenji , Azemoto Ryosaku , Atsukawa Masanori , Itobayashi Ei , Kato Naoya
Published: December 2023

Response to lenvatinib in 57 patients for efficacy analysis
(evaluation by each investigator)
Data from A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy
Authors: Grierson Patrick M. , Suresh Rama , Tan Benjamin , Pedersen Katrina S. , Amin Manik , Park Haeseong , Trikalinos Nikolaos A. , Liu Jingxia , Boice Nicholas , Brown Amberly , Bansod Sapana , Wang-Gillam Andrea , Lim Kian-Huat
Published: December 2023

AbstractPurpose:
Vitamin D analogues remodel the desmoplastic stroma, and improve vascularity and efficacy of chemotherapy in preclinical pancreas cancer models.
Patients and Methods:
We conducted a pilot study to evaluate the safety and preliminary efficacy of the vitamin D analogue paricalcitol in combination with nanoliposomal irinotecan (Nal-iri) plus 5-fluorouracil/leucovorin (5-FU/LV) in patients with advanced pancreatic cancer who had progressed on gemcitabine-based therapy. Two dose levels (DL) of paricalcitol were tested: fixed dose weekly (75 mcg, DL1) and weight-based weekly (7 mcg/kg, /DL2). The primary endpoint was safety, and secondary endpoints included overall response rate, progression-free survival (PFS), and overall survival (OS). Correlative objectives aimed to identify molecular predictors of response and alterations in the tumor stroma.
Results:
Twenty patients (10 each in DL1 and DL2) enrolled between March 2019 and May 2021. No grade 3/4 adverse events related to paricalcitol were observed. The most common toxicities were nausea, diarrhea and fatigue, which were similar in both cohorts. Three patients discontinued study after one cycle and were not radiographically evaluable. Of the remaining 17 evaluable patients, 2 had partial response and 12 had stable disease. The median PFS for response-evaluable patients in DL1 was 4.14 months, for DL2 was 4.83 months. Intent-to-treat median OS was 6.15 and 6.66 months for DL1 and DL2, respectively. Correlative studies showed increased tumor vascularity in posttreatment samples in patients receiving the higher dose of paricalcitol (DL2).
Conclusions:
Paricalcitol at 7 mcg/kg/week in combination with Nal-iri/ 5-FU/LV is safely tolerated, may increase tumor vascularity and warrants further investigation.
Abstract IA008: Weaving university and community-based partnership
Authors: Sanderson Priscilla R. , Monroy Fernando , Brown Heidi , Harris Robin
Published: December 2023

Introduction/Background Including Hypothesis/Objectives: University investigators affiliated with the Partnership for Native American Cancer Prevention (NACP) and Navajo Nation partners worked together with a goal to estimate the prevalence of Helicobacter pylori infection and its specific subtypes and factors associated with infection. Methods: This partnership required multiple strategies to promote awareness and individual participation in this study. The team started with tribal resolutions and communication network with local Chapter House officers, Community Health Representatives (CHRs), local Navajo translators, Diné Haatalii Association (Navajo Medicine Man), social network outreach, and community healthcare providers.   Results: Our population-based study weaved together various networks with local leaders, social media, and the Navajo Healthy Stomach website. Participant follow-up after testing found that local hospitals were overwhelmed with requests for appointments and immediate treatment. Participants reported side-effects of prescribed medications. The Monroy lab revealed enough biopsies to test for Helicobacter pylori infection.   Conclusions: Successful studies must utilize both Navajo Nation Human Research and Review Board approvals with university Institutional Review Boards (IRBs). Local, in-person, radio, and social media-based weaving of culturally sensitive communications develops strong partnerships between university and community-based local people, programs, and hospitals.  Future Directions (Opportunities and Challenges): The team continues to study the role of Helicobacter pylori on the gastrointestinal microbiome in the development of gastric disease in infected Navajo patients. Further outreach is ongoing with local community and providers. Funding Support: Partnership for Native American Cancer Prevention, U54 NCI grant.

Citation Format: Priscilla R. Sanderson, Fernando Monroy, Heidi Brown, Robin Harris. Weaving university and community-based partnership [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr IA008.
Data from Competing Engagement of β-arrestin Isoforms Balances IGF1R/p53 Signaling and Controls Melanoma Cell Chemotherapeutic Responsiveness
Authors: Cismas Sonia , Pasca Sylvya , Crudden Caitrin , Trocoli Drakensjo Iara , Suleymanova Naida , Zhang Simin , Gebhard Benjamin , Song Dawei , Neo Shiyong , Shibano Takashi , Smith Terry J. , Calin George A. , Girnita Ada , Girnita Leonard
Published: December 2023

Abstract
Constraints on the p53 tumor suppressor pathway have long been associated with the progression, therapeutic resistance, and poor prognosis of melanoma, the most aggressive form of skin cancer. Likewise, the insulin-like growth factor type 1 receptor (IGF1R) is recognized as an essential coordinator of transformation, proliferation, survival, and migration of melanoma cells. Given that β-arrestin (β-arr) system critically governs the anti/pro-tumorigenic p53/IGF1R signaling pathways through their common E3 ubiquitin-protein ligase MDM2, we explore whether unbalancing this system downstream of IGF1R can enhance the response of melanoma cells to chemotherapy. Altering β-arr expression demonstrated that both β-arr1-silencing and β-arr2-overexpression (-β-arr1/+β-arr2) facilitated nuclear-to-cytosolic MDM2 translocation accompanied by decreased IGF1R expression, while increasing p53 levels, resulting in reduced cell proliferation/survival. Imbalance towards β-arr2 (-β-arr1/+β-arr2) synergizes with the chemotherapeutic agent, dacarbazine, in promoting melanoma cell toxicity. In both 3D spheroid models and in vivo in zebrafish models, this combination strategy, through dual IGF1R downregulation/p53 activation, limits melanoma cell growth, survival and metastatic spread. In clinical settings, analysis of the TCGA-SKCM patient cohort confirms β-arr1−/β-arr2+ imbalance as a metastatic melanoma vulnerability that may enhance therapeutic benefit. Our findings suggest that under steady-state conditions, IGF1R/p53-tumor promotion/suppression status-quo is preserved by β-arr1/2 homeostasis. Biasing this balance towards β-arr2 can limit the protumorigenic IGF1R activities while enhancing p53 activity, thus reducing multiple cancer-sustaining mechanisms. Combined with other therapeutics, this strategy improves patient responses and outcomes to therapies relying on p53 or IGF1R pathways.
Implications:
Altogether, β-arrestin system bias downstream IGF1R is an important metastatic melanoma vulnerability that may be conductive for therapeutic benefit.
Impactos das Cotas Sociais e Raciais no Perfil Socioeconômico dos Estudantes da FFLCH, USP
Authors: Girotto Eduardo Donizeti , Garcia Sylvia Gemignani , Silva Patrícia Paula da , Carmo Waldirene Ribeiro do , Soares Anna Clara Pereira , Lima Jacquelline Evaristo Guedes de , Lanzarini João Paulo , Ferreira Julia Gimenes Candido , Nogueira Willer
Published: December 2023

O presente artigo, resultado de pesquisa desenvolvido no projeto “Construindo uma política interdisciplinar de acolhimento das/dos ingressantes na FFLCH”, financiado pelo edital Consórcios Acadêmicos para a Excelência no Ensino de Graduação, da Pró-Reitoria de Graduação da USP, tem como principal objetivo compreender os possíveis impactos da adoção das cotas sociais e raciais sobre o perfil socioeconômico dos estudantes da FFCLH, analisando sua variação conforme as diferentes modalidades de cotas adotadas. Para tanto, analisa dados de questionário aplicado aos estudantes matriculados na unidade em 2023, correlacionado os resultados a partir de dois recortes: estudantes cotistas e não cotistas e ingressantes a partir das diferentes modalidades de cotas existentes na FFLCH/USP. Os resultados indicam que a adoção das cotas já possibilita uma mudança de perfil dos estudantes da FFLCH, na direção de aproximá-lo daquele encontrado na composição geral da população paulista. Além disso, indicam a importância da adoção das cotas raciais, uma vez que a adoção de cotas de escola pública e de renda, no conjunto de dados analisados, não foram suficientes para ampliar a diversidade racial da FFLCH, aproximando-a daquela encontrada na composição geral da população paulista.
Concepções de Licenciandos em Química sobre a Construção do Conhecimento Científico: Análise a partir de Textos sobre a Produção da Bomba Atômica
Authors: Silva Guilherme Balestiero da , Alves Pabllo Abreu , Queiroz Salete Linhares
Published: December 2023

O entendimento sobre a construção do conhecimento científico por parte dos licenciandos em química é componente essencial para a sua formação, principalmente devido à influência direta que terão, como futuros profissionais, na elaboração das concepções dos estudantes da educação básica sobre o assunto. Este trabalho investigou concepções de licenciandos em química a respeito da construção do conhecimento científico a partir da análise de textos argumentativos de sua autoria relacionados à criação da primeira bomba atômica, Trinity. Para tanto, foram consideradas sete visões deformadas do trabalho científico, assim como cinco características essenciais do trabalho científico reportadas na literatura. As análises mostraram ausência de visões distorcidas da ciência em todos os textos e indícios de compreensão dos estudantes acerca do caráter social da ciência.
Comparing Efficacy and Safety Between Patients With Atrial Fibrillation Taking Direct Oral Anticoagulants or Warfarin After Direct Oral Anticoagulant Failure
Authors: Hsieh Meng‐Tsang , Liu Chi‐Hung , Lin Sheng‐Hsiang , Lin Po‐Yu , Chang Yu‐Ming , Wang Chun‐Min , Chen Chih‐Hung , Sung Pi‐Shan
Published: December 2023

Background

An increased risk of recurrent stroke is noted in patients with atrial fibrillation despite direct oral anticoagulant (DOAC) use. We investigated the efficacy and safety of treatment with each of 4 different DOACs or warfarin after DOAC failure.

Methods and Results

We retrospectively analyzed patients with atrial fibrillation with ischemic stroke despite DOAC treatment between January 2002 and December 2016. The different outcomes of patients with DOAC failure were compared, including recurrent ischemic stroke, major cardiovascular events, intracranial hemorrhage and subarachnoid hemorrhage, mortality, and net composite outcomes according to switching to different DOACs or vitamin K antagonist after index ischemic stroke. We identified 3759 patients with DOAC failure. A total of 84 patients experienced recurrent ischemic stroke after switching to different oral anticoagulants, with a total follow‐up time of 14 years. Using the vitamin K antagonist group as a reference, switching to any of the 4 DOACs was associated with a 69% to 77% reduced risk of major cardiovascular events (adjusted hazard ratio [aHR], 0.25 [95% CI, 0.16–0.39] for apixaban, 0.23 [95% CI, 0.14–0.37] for dabigatran, 0.23 [95% CI, 0.09–0.60] for edoxaban, and 0.31 [95% CI, 0.21–0.45] for rivaroxaban), and a 69% to 83% reduced risk of net composite outcomes (aHR, 0.25 [95% CI, 0.18–0.35] for apixaban, 0.17 [95% CI, 0.11–0.25] for dabigatran, 0.31 [95% CI, 0.17–0.56] for edoxaban, and 0.31 [95% CI, 0.23–0.41] for rivaroxaban).

Conclusions

In Asian patients with DOAC failure, continuing DOACs after index stroke was associated with fewer undesirable outcomes than switching to a vitamin K antagonist. Alternative pharmacologic and nonpharmacologic strategies warrant investigation.
Chromosome 10q24.32 Variants Associate With Brain Arterial Diameters in Diverse Populations: A Genome‐Wide Association Study
Authors: Liu Minghua , Khasiyev Farid , Sariya Sanjeev , Spagnolo‐Allende Antonio , Sanchez Danurys L , Andrews Howard , Yang Qiong , Beiser Alexa , Qiao Ye , Thomas Emy A , Romero Jose Rafael , Rundek Tatjana , Brickman Adam M , Manly Jennifer J , Elkind Mitchell SV , Seshadri Sudha , Chen Christopher , Hilal Saima , Wasserman Bruce A , Tosto Giuseppe , Fornage Myriam , Gutierrez Jose
Published: December 2023

Background

Brain arterial diameters (BADs) are novel imaging biomarkers of cerebrovascular disease, cognitive decline, and dementia. Traditional vascular risk factors have been associated with BADs, but whether there may be genetic determinants of BADs is unknown.

Methods and Results

The authors studied 4150 participants from 6 geographically diverse population‐based cohorts (40% European, 14% African, 22% Hispanic, 24% Asian ancestries). Brain arterial diameters for 13 segments were measured and averaged to obtain a global measure of BADs as well as the posterior and anterior circulations. A genome‐wide association study revealed 14 variants at one locus associated with global BAD at genome‐wide significance (
P
<5×10
−8
) (top single‐nucleotide polymorphism, rs7921574; β=0.06 [
P
=1.54×10
−8
]). This locus mapped to an intron of
CNNM2
. A trans‐ancestry genome‐wide association study meta‐analysis identified 2 more loci at
NT5C2
(rs10748839;
P
=2.54×10
−8
) and
AS3MT
(rs10786721;
P
=4.97×10
−8
), associated with global BAD. In addition, 2 single‐nucleotide polymorphisms colocalized with expression of
CNNM2
(rs7897654; β=0.12 [
P
=6.17×10
−7
]) and
AL356608.1
(rs10786719; β=−0.17 [
P
=6.60×10
−6
]) in brain tissue. For the posterior BAD, 2 variants at one locus mapped to an intron of
TCF25
were identified (top single‐nucleotide polymorphism, rs35994878; β=0.11 [
P
=2.94×10
−8
]). For the anterior BAD, one locus at
ADAP1
was identified in trans‐ancestry genome‐wide association analysis (rs34217249;
P
=3.11×10
−8
).

Conclusions

The current study reveals 3 novel risk loci (
CNNM2
,
NT5C2
, and
AS3MT
) associated with BADs. These findings may help elucidate the mechanism by which BADs may influence cerebrovascular health.
The Essence of Consciousness Eludes Psychology as a Science of the Palpable
Authors: Giorgi Amedeo
Published: December 2023

Historians of psychology are aware that, at its beginning, psychology had a choice with respect to the type of science it was going to be. It could be a content type psychology using the experimental method as proposed by Wundt or a basic empirical psychology founded on acts of consciousness explicated through critical analyses and careful descriptions of psychological phenomena as proposed by Brentano. As noted by Boring, because content was palpable and acts seemed elusive, Wundt’s experimental psychology prevailed. But Watson believed that, as they were themselves still difficult to detect, the content of conscious processes were not sufficiently palpable. So, he advocated using behavior as the basis for experimental psychology. Yet palpability is essential for the experimental method, not for studying consciousness. Intentionality is the essence of consciousness, but it is not palpable, though detectable. In the teens and twenties of the 19th Century some German psychologists developed a type of bipartite psychology that included both acts and content, but their work remained isolated.
An Expensive Pass to Freedom: Bond Amounts Trajectories in Immigration Court
Authors: Avila Lorena , Ibañez David
Published: December 2023

Thousands of immigrants are in civil detention awaiting case adjudication in the United States. Unguaranteed legal representation and stringent access to bond hearings restrict the chances of release. Though the institutional purpose of civil detention and bonds in Immigration Court is to secure safety and the public good, we find contradictions in such purpose: increasingly high bonds are mandated regardless of individual circumstances, in a context of legal violence, or the loss and uncertainty experienced by a subclass of individuals scrutinized by the law, characterized by heightened criminalization, scarce legal protections, and broad judicial discretion. We use bond case administrative data from the Executive Office of Immigration Review between 1991 and 2020 in a multivariate analysis that centers on the influence of criminal records and legal representation to get lower bond amounts granted. We find that criminal records predict risk before 2001, but after, individuals with no records are also mandated to pay higher amounts to Immigration Courts. After 2001, legal representation’s influence on reducing bond amounts is subtle but relevant. We analyze these findings in light of policy changes and provide evidence on how increasingly high bonds fracture social and economic determinants of immigrants’ well-being by altering their economic stability while they and their communities also suffer the psychological and physical tolls of detention.
Towards Deciphering Shared Spaces Among Religious Groups in Contemporary Indian Society: Some Illustrations and Challenges
Authors: Singh Purnima , Misra Girishwar , Kapur Preeti , Mishra Arvind K. , Siddiqui Roomana
Published: December 2023

This article presents the concept of shared spaces among religious groups in the contemporary Indian context. In the land of unity in diversity which India is known to be, this article showcases some illustrations of attempts to build shared spaces historically through religion, social arrangements, and interfaith communications and discusses the challenges in this journey. It is argued that through shared spaces, people come together, feel closeness and engage in acts of reciprocity, cooperation, and mutual celebration. Such shared spaces have permeable boundaries. The boundaries can be either barriers or bridges. Attempts to create bridges will foster peace and harmony.
Rationalisation of Schools and Its Impact on Children’s Right to Education: Narratives of Violation of the RTE Act 2009
Authors: Sharma Aparajita , Mitra Susmita
Published: December 2023

The school rationalisation process in India led to the closure/merger of many public schools in the country. This closure/merger has been contested widely on the grounds that it might have a negative consequence for the marginalised children, who could break the age-old barriers and ‘access’ school education owing to the Right to Education (RTE) Act, 2009. The article, through a case study method in seven southern districts of Rajasthan exploring the rationalisation policy vis-à-vis the RTE Act, found that the closure/merger process lacked transparency, was done without proper mapping, and, thus, violated many of the RTE norms and standards. We argue that the policy of rationalisation led to a violation of the RTE Act in many ways, curtailing the role of small schools, which played a major role in the universalisation of elementary education.
Book review: Sarah Lamb. 2022. Being Single in India: Stories of Gender, Exclusion and Possibility
Authors: Bhandari Parul
Published: December 2023

Sarah Lamb. 2022. Being Single in India: Stories of Gender, Exclusion and Possibility. Berkeley: University of California Press. xi + 221 pp. Illustrations, notes, references, index. (Ebook, open access—ISBN 9780520389427).
Book review: Shailaja Paik. 2022. The Vulgarity of Caste: Dalits, Sexuality, and Humanity in Modern India
Authors: Suneetha A.
Published: December 2023

Shailaja Paik. 2022. The Vulgarity of Caste: Dalits, Sexuality, and Humanity in Modern India. Stanford: Stanford University Press. 400 pp. Notes, bibliography and index. ₹2390 (paperback—ISBN: 9781503634084).
Book review: Gayatri Nair. 2021. Set Adrift: Capitalist Transformations and Community Politics along Mumbai’s Shore
Authors: Jairath Vasundhara
Published: December 2023

Gayatri Nair. 2021. Set Adrift: Capitalist Transformations and Community Politics along Mumbai’s Shore. Delhi: Oxford University Press. xiv + 202 pp. Tables, figures, bibliography, index. ₹1295 (hardback— ISBN: 9780190130244).
Book review: Mohita Bhatia. 2020. Rethinking Conflict at the Margins: Dalits and Borderland Hindus in Jammu and Kashmir
Authors: Fazili Gowhar
Published: December 2023

Mohita Bhatia. 2020. Rethinking Conflict at the Margins: Dalits and Borderland Hindus in Jammu and Kashmir. Cambridge: Cambridge University Press. 211 pp. Footnotes, glossary, bibliography. ₹790. (hardback—ISBN 9781108836029)